Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
Conditions
Interventions
XF-73
Placebo
Locations
21
United States
University of Florida
Gainesville, Florida, United States
Snake River Research, PLLC
Pocatello, Idaho, United States
MercyOne Iowa Heart Center
Des Moines, Iowa, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
University of Missouri Health Care
Columbia, Missouri, United States
Memorial Hermann - Memorial City Medical Center
Houston, Texas, United States
Start Date
August 29, 2019
Primary Completion Date
January 4, 2021
Completion Date
March 29, 2021
Last Updated
October 16, 2023
NCT06848387
NCT06378359
NCT07003906
NCT06626399
NCT03561376
NCT06869096
Lead Sponsor
Destiny Pharma Plc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions